Phase 3 ARISE trial of solengepras, a potential first-in-class non-dopaminergic therapy, is fully enrolled and topline data ...

Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the ...

Gain Therapeutics, Inc. (Nasdaq: GANX) ('Gain”, or the 'Company”), a clinical-stage biotechnology company leading the ...

Ten years after being diagnosed with Parkinson’s disease, South Australian football great Mark Mickan is upping the ante in ...

Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers expected in H2 2026 Initiated final cohort, AD4, in ABATE ...

Remembering the moment, he breaks down how he felt: 70% relief and 30% uncertainty ...

While Parkinson’s disease won’t kill him, it did change the trajectory of the remaining years of his life. Parkinson’s disease is the second-most common neurological condition in the world, yet still ...

Share on Pinterest Changes in gut health may serve as an early marker of Parkinson’s disease, according to new research. Studio Firma/Stocksy A new study suggests that gut health may be linked to ...

A growing body of evidence suggests that at least some cases of Parkinson’s disease may start in the gut, through the spread of an abnormal protein from the stomach to the brain, a process that is ...

7NEWS cameras were inside the clinic to witness the moment Walter Grkovic became the first patient in Australia to receive ...

More than half of adults say immigration levels are too high and 30 per cent of voters have swung to One Nation. What’s the truth about our immigration numbers?